文献速递基础与转化研究医学人工智能与信息学新药、器械与细胞基因治疗研发

结核病候选联合方案的筛选与优先排序

Selection and prioritization of candidate combination regimens for the treatment of tuberculosis.
PubMed 文献 · Sci Transl Med · 2025-02-05

研究利用小鼠结核模型的公开疗效数据,构建并外部验证整合数学模型预测复发,对18个候选方案(含11种药物)的2965次复发和1544次菌落形成单位观察进行分析;锁定模型AUROC为0.910,验证实验AUROC为0.829,二芳基喹啉类预测杀菌活性最高,加用吡嗪酰胺可缩短治愈疗程。

要点

  • 锁定数学模型预测小鼠复发的AUROC为0.910,外部验证AUROC为0.829。
  • 纵向菌落形成单位所测细菌杀灭不能单独解释复发,灭菌具有药物依赖性。
  • 二芳基喹啉类在小鼠模型中预测灭菌活性最高,加用吡嗪酰胺的方案估计治愈疗程最短。

核心结论

  • 数学模型能预测治疗组合的效果,并在11项未研究方案的实验中获验证,AUROC为0.829。
  • 作者推测下一代结核药物在缩短疗程方面高度有效,并建议若干有前景的三药和四药方案推进临床试验。

研究设计与样本

  • 利用已发表的小鼠结核模型疗效数据,训练并外部验证整合数学模型以预测小鼠复发并对方案排序。
  • 生成18个候选方案(含6类11种药物,包括氟喹诺酮类、硝基咪唑类、二芳基喹啉类和噁唑烷酮类)的18个数据集,含2965次复发和1544次菌落形成单位观察。
  • 应用统计和机器学习技术预测小鼠复发概率。

主要发现

  • 锁定数学模型预测复发的AUROC为0.910。
  • 以纵向菌落形成单位衡量的细菌杀灭不能单独解释复发,灭菌具有药物依赖性。
  • 二芳基喹啉类在小鼠模型中预测灭菌活性最高。
  • 加用吡嗪酰胺的方案估计小鼠治愈所需结核治疗时长最短。
  • 对11项未研究方案进行实验验证,AUROC为0.829。

关键数值与推荐

  • 锁定数学模型AUROC为0.910。
  • 外部验证实验AUROC为0.829。

临床怎么用

  • 作者建议若干有前景的三药和四药方案推进临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accelerated tuberculosis drug discovery has increased the number of plausible multidrug regimens. Testing every drug combination in vivo is impractical, and varied experimental conditions make it challenging to compare results between experiments. Using published treatment efficacy data from a mouse tuberculosis model treated with candidate combination regimens, we trained and externally validated integrative mathematical models to predict relapse in mice and to rank both previously experimentally studied and unstudied regimens by their sterilization potential. We generated 18 datasets of 18 candidate regimens (comprising 11 drugs of six classes, including fluoroquinolone, nitroimidazole, diarylquinolines, and oxazolidinones), with 2965 relapse and 1544 colony-forming unit (CFU) observations for analysis. Statistical and machine learning techniques were applied to predict the probability of relapse in mice. The locked down mathematical model had an area under the receiver operating characteristic curve (AUROC) of 0.910 and showed that bacterial kill measured by longitudinal CFU cannot account for relapse alone and that sterilization is drug dependent. The diarylquinolines had the highest predicted sterilizing activity in the mouse model, and the addition of pyrazinamide to drug regimens provided the shortest estimated tuberculosis treatment duration to cure in mice. The mathematical model predicted the effect of treatment combinations, and these predictions were validated by conducting 11 experiments on previously unstudied regimens, achieving an AUROC of 0.829. We surmise that the next generation of tuberculosis drugs are highly effective at treatment shortening and suggest that there are several promising three- and four-drug regimens that should be advanced to clinical trials.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Strydom N, van Wijk RC, Wang Q, et al. Selection and prioritization of candidate combination regimens for the treatment of tuberculosis. Sci Transl Med. 2025. PMID: 39908348. doi:10.1126/scitranslmed.adi4000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。